AbbVie investors lukewarm on Pharmacyclics deal

AbbVie Inc. (NYSE:ABBV) shed $3.41 to $56.86 on news of its $21 billion acquisition of oncology play Pharmacyclics Inc. (NASDAQ:PCYC), a signal that shareholders are questioning whether the deal will fill AbbVie's revenue gap as the company looks to reduce its dependence on blockbuster Humira adalimumab.

When Abbott Laboratories announced plans in 2011

Read the full 539 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE